Innovation in action

We continue to pursue pioneering solutions that drive genetic improvement for customers.

Dr Elena Rice
Chief Scientific Officer and Head of R&D

STRATEGIC PROGRESS IN FY26

Gene editing

- Achieved regulatory approval for the EverThrive® PRP in Canada, an important step towards commercialising the product in North America.
- Maintained positive engagement regarding the EverThrive® PRP with regulators in Mexico, Japan, China and other international jurisdictions.
- Harnessed our stem-cell-based gene-editing platform to accelerate progress on projects to combat additional diseases, including African Swine Fever.

Innovative technology

- Made further progress with evolving our sexing technology, offering prospective advances in areas such as skew, throughput and automation.
- Continued to enhance the development and application of insights from genomic data, to help our businesses drive genetic gain.

Data strategy

- Introduced centralised instrument monitoring – which enables remote interaction with sexing instruments and rapid intervention if needed – to our sexing lab in Leeds (US), as a precursor to deploying the software to support other sites around the world.
- Continued to strengthen our scientific data platform, enabling us to integrate more diverse data sources, improve scalability and accelerate the deployment of robust insights.

BUSINESS PRIORITIES

Short term

Obtain further regulatory approvals for the EverThrive® PRP in target markets around the world.

Medium term

Maximise use of our pioneering technologies, including our stem-cell-based gene-editing platform, bovine sexing instrumentation and reproductive technology.

Long term

Develop or license further technologies that could accelerate genetic gain, combat livestock disease or support a more sustainable global food system.

Operating Review / R&D continued

Twelve months ended 30 June	Actual currency 2026 £m	Actual currency 2025 £m	Actual currency Change %	Constant currency Change %
Gene editing	**(3.5)**	(4.3)	**(19)**	(16)
Other research and development	**(11.2)**	(12.2)	**(8)**	(5)
Net expenditure in R&D	**(14.7)**	(16.5)	**(11)**	(8)

Net expenditure on R&D decreased 11% in constant currency in FY26 and represented 2.2% of Group revenue. Net expenditure on R&D is expected to increase in FY27 but remain below 3% of Group revenue. R&D's key near-term focus is achieving PRP regulatory approvals and in the medium term we remain excited by opportunities in disease resistance and reproductive technology.

The Science and Economic Promise of PRRS-Resistant Pigs

PRRS has affected pig producers for nearly 40 years. In this video, leading experts discuss the impact of the disease and how gene editing could help address one of the swine industry's most significant challenges.

Scan QR code to read full testimonial